PAC3 Inhibitors
PAC3 inhibitors are a category of chemical compounds that interact with the proteasome assembly chaperone 3 (PAC3), a protein that is integral to the proper assembly and function of the proteasome complex. The proteasome is a pivotal enzyme cluster within cellular systems responsible for degrading unneeded or damaged proteins by proteolysis, a chemical process that breaks down peptides into amino acids. This process is crucial for maintaining cellular homeostasis, regulating protein concentration, and removing proteins that could be deleterious to cell function if left unprocessed. PAC3 facilitates the correct assembly of the 20S core particle of the proteasome, ensuring that proteolysis is carried out efficiently and accurately. Inhibitors that target PAC3 work by interfering with this protein's function, affecting the assembly of the proteasome and subsequently its proteolytic activity.
The design and development of PAC3 inhibitors are grounded in the understanding of the protein's structure and its role in the formation of the proteasome. By binding to the PAC3 protein, these inhibitors can disrupt the interactions necessary for the proteasome to form correctly, which in turn affects the protein degradation pathway. These inhibitors are typically small molecules that can specifically bind to the active or allosteric sites of PAC3, impeding its chaperone function. The specificity of these compounds is crucial, as it determines their ability to selectively target PAC3 without affecting other proteins or cellular functions. These inhibitors are often identified and optimized through various methods, including high-throughput screening, computational modeling, and structure-activity relationship studies, which help in refining their ability to bind to the PAC3 with high affinity and selectivity. The study of PAC3 inhibitors is driven by an interest in the fundamental cellular mechanisms of protein degradation and the complex interplay of proteins involved in the proteasomal pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTORC1 pathway, which is crucial for protein synthesis and cell growth. PAC3 activity is reliant on these cellular processes; therefore, inhibition of mTORC1 by Rapamycin leads to a reduction in PAC3 activity due to decreased protein synthesis and cell growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT/mTOR signaling pathway. By inhibiting PI3K, LY294002 reduces AKT phosphorylation and subsequent mTOR activation. This results in decreased PAC3 activity as the pathway is crucial for cell survival and proliferation, processes in which PAC3 is involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts similarly to LY294002. It also impedes the PI3K/AKT/mTOR cascade, leading to diminished PAC3 activity by preventing cellular processes that are essential for PAC3’s functional role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that interrupts the MAPK/ERK pathway. Since PAC3 operates downstream of this pathway, the inhibition of MEK and subsequent suppression of ERK phosphorylation indirectly leads to reduced PAC3 activity by limiting cell differentiation and proliferation signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also an inhibitor of MEK, which operates in the MAPK/ERK pathway. By inhibiting MEK, U0126 hinders ERK activation, leading to decreased PAC3 activity as the MAPK/ERK pathway is integral to the processes that govern the functional activity of PAC3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can interfere with the p38 MAPK signaling pathway. PAC3 function is modulated through this pathway, which is involved in inflammatory responses and stress stimuli. Inhibition of p38 MAPK by SB203580 results in the attenuation of PAC3 activity due to the disruption of these cellular response processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK family. Inhibiting JNK leads to decreased PAC3 activity by disrupting the signaling involved in cellular stress responses, apoptosis, and inflammation, processes in which PAC3 has been implicated. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor that can indirectly decrease PAC3 activity by blocking the RAF/MEK/ERK pathway. This blockade results in the downregulation of processes such as cell proliferation and angiogenesis, which are essential for PAC3 activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets multiple pathways, including PDGFR and VEGFR. These pathways influence cellular processes vital for PAC3 activity. By inhibiting these receptors, Sunitinib indirectly reduces PAC3 functional activity by decreasing cell proliferation and angiogenesis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that suppresses the EGFR signaling pathway. Since PAC3 activity is modulated by downstream effects of EGFR signaling, which include cell proliferation and survival, inhibition of EGFR by Gefitinib leads to a reduction in PAC3 activity. | ||||||